SOURCE: Kinexium

March 11, 2008 08:00 ET

Zoe Heineman Myers Expands Kinexum's Expertise in the Diabetes Sector

Strategic Marketing, Communication and Education Services Are a Key Component for Companies Developing New Products

BURNSVILLE, MN--(Marketwire - March 11, 2008) - Kinexum is pleased to announce that Zoe Heineman Myers has joined their team of professional consultants to provide strategic development and marketing services for clients in the diabetes, metabolic syndrome and anti-aging sectors. Ms. Heineman Myers brings extensive experience in advancing healthcare product development and market education. Her past industry experience includes Vice President of North America Sales & Field Operations at Disetronic Medical Systems, Inc. which was purchased by Roche Diagnostics Corporation in 2003.

"Zoe's experience in sales, marketing education and reimbursement issues for therapeutics and devices will be an asset for our organization, as it bridges the development and commercialization phases of healthcare products," stated Dr. Alexander Fleming, founder and president of Kinexum. Heineman Myers is a passionate advocate for the intensive management of diabetes and testified in 2006 before the House Health & Government Operations and Appropriations Committees in support of research initiatives for Type 1 Diabetes. She joins the team of experts at Kinexum who provide regulatory strategy and clinical development services to numerous companies involved in the development of healthcare products for diabetes, metabolic syndrome, anti-aging and oncology. Heineman Myers will serve as the Vice President of Strategic Marketing and Communication for Kinexum.

Heineman-Myers to Lead Communication Strategy for INGAP Peptide

Ms. Heineman Myers will lead the communication strategy for INGAP Peptide as Kinexum Metabolics, Inc. (KMI) advances into Phase 2 clinical trials. KMI is the development company founded by Dr. Fleming to pursue novel therapies to meet unmet clinical needs for diabetes and metabolic disorders. KMI is moving forward with plans to test a refined formulation and delivery regimen in Type 1 diabetes with support from private donations in Canada. INGAP is a therapeutic approach that regenerates fully functional islet cells, which secrete insulin and other important hormones. This approach could benefit all people with Type 1 diabetes. "I have advocated for new approaches in diabetes treatment and intensive management, and have been involved in the earliest stages of educating healthcare providers and payers as new products come to market. Returning insulin secretion will enable the person who lives with Type 1 diabetes to achieve better glucose control with less risk of hypoglycemia. INGAP therefore has the potential to provide immense clinical and quality of life benefits for patients and families touched by this disease," states Ms. Heineman Myers. "We will greatly benefit from Zoe Heineman Myers' energy and expert guidance in strategic communications and education for this novel area of diabetes therapeutic development," remarks Dr. Fleming.

About Kinexum (

Kinexum is a strategic consulting firm providing regulatory and clinical development services to healthcare product development companies worldwide. Kinexum Metabolics, Inc. is a biopharmaceutical company focused on the development of therapies for the treatment of Type 1 and Type 2 diabetes and other metabolic conditions.

Contact Information